Skip to content

Study · Case report or series · n = 3 · 2012

2 results

Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases.

Lee YK, Ha YC, Koo KH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA18 Oct 2012Cited by 44 (Europe PMC)

PMID23076681 (opens in a new tab)DOI10.1007/s00198-012-2172-x (opens in a new tab)PepBankPUB-23076681
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In three patients with femoral nonunion, teriparatide treatment was followed by successful union without further surgery.

    In plain wordsIn three patients with thighbone nonunion, bone union occurred after teriparatide without further surgery.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableFemoral nonunion healing
    Study

    n = 3

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 3-9 monthsAs given in this study (human).

    Source sentences

    Summary
    A successful union was obtained in all three patients without further surgical intervention, and no adverse events related to the use of teriparatide were observed.
    2 context sentences
    Summary · context
    We medicated teriparatide in three patients, who had a nonunion of the femur even after the initial surgical intervention.
    Summary · context
    Teriparatide was administered for 3-9 months after a diagnosis of nonunion.
  2. 02HumanCase report or seriesSafety outcome

    In three patients with femoral nonunion, no adverse events related to teriparatide were observed.

    In plain wordsIn three patients with thighbone nonunion, no adverse events related to teriparatide were observed.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableTreatment-related adverse events
    Study

    n = 3

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 3-9 monthsAs given in this study (human).

    Source sentences

    Summary
    A successful union was obtained in all three patients without further surgical intervention, and no adverse events related to the use of teriparatide were observed.
    2 context sentences
    Summary · context
    We medicated teriparatide in three patients, who had a nonunion of the femur even after the initial surgical intervention.
    Summary · context
    Teriparatide was administered for 3-9 months after a diagnosis of nonunion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.